<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02718430</url>
  </required_header>
  <id_info>
    <org_study_id>VXM01-03-DE</org_study_id>
    <nct_id>NCT02718430</nct_id>
  </id_info>
  <brief_title>VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis</brief_title>
  <official_title>VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis Under Second or Third Line Therapy to Examine Safety, Efficacy, and Immune Biomarkers After Treatment With VXM01</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vaximm GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vaximm GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I study in patients with metastatic colorectal cancer with liver metastasis under
      second or third line therapy to examine safety, efficacy, and immune biomarkers after
      treatment with VXM01
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability taking into account treatment-limiting toxicities (TLTs)</measure>
    <time_frame>18 months</time_frame>
    <description>AEs listed together with information on onset, duration, severity, seriousness, relationship to the study drug, relationship to chemotherapy and to the underlying disease, outcome, and action taken. Frequency tables by System Organ Class and preferred term.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune Response by Enzme Linked Immuno Spot (ELISpot)</measure>
    <time_frame>18 months</time_frame>
    <description>Patient-individual VEGFR-2 specific T-cell responses determined by ELISpot using cryopreserved peripheral blood mononuclear cells (PBMC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune biomarker by tumor tissue immunohistochemistry staining</measure>
    <time_frame>66 days</time_frame>
    <description>Immune biomarker including T-cell infiltration, Treg, myeloid derived suppressor cells (MDSC) by tumor tissue immunohistochemistry staining</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor vasculature by tumor tissue immunohistochemistry staining</measure>
    <time_frame>66 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum biomarker Response by Enzyme Linked Immuno Sorbent Assay (ELISA)</measure>
    <time_frame>18 months</time_frame>
    <description>Serum VEGF A and collagen IV measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response including tumor staging according to the response criteria in solid tumors (RECIST)</measure>
    <time_frame>18 months</time_frame>
    <description>Tumor staging according to the response criteria in solid tumors (RECIST) and investigation of the primary tumor and metastasis, e.g., determination of primary tumor size, number and size of metastasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biodistribution and shedding of VXM01</measure>
    <time_frame>10 days</time_frame>
    <description>Bacterial vector tissue biodistribution, persistence, and shedding of viable Ty21a bacteria (VXM01) determined by cultivation of stool samples</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>VXM01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VXM01 10E6 or 10E7 CFU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VXM01</intervention_name>
    <description>Oral immunotherapy targeting VEGFR2</description>
    <arm_group_label>VXM01</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent, including liver metastasis biopsy, signed and dated

          2. Histologically or cytologically confirmed colorectal cancer, excluding primary tumors
             of appendiceal origin (participants are eligible to enroll irrespective of Kirsten rat
             sarcoma viral oncogene homolog (KRAS) mutation status)

          3. Male or female patients who must be post-menopausal for at least 2 years or surgically
             sterile.

          4. Confirmed metastatic colorectal cancer (Stage IV)

          5. Presence of non-resectable liver metastasis

               -  Accessibility of liver metastasis appropriate for biopsy sampling

               -  Adequate coagulation parameters including platelet count ≥100,000/mm3

               -  Absence of concomitant medication which could represent a contraindication for
                  biopsy (e.g., anti-platelet drugs including aspirin, ticlopidine, clopidogrel,
                  IIb/IIIa receptor antagonists, non-steroidal anti-inflammatory drugs [NSAIDs],
                  and vitamin K antagonist anticoagulants)

          6. The participant has received first-line irinotecan- or oxaliplatin-based therapy
             without or in combination with a targeted antibody for metastatic disease and a)
             Experienced radiographic disease progression during first-line therapy, or b)
             Experienced radiographic disease progression ≤ 6 months after the last dose of
             first-line therapy, or c) Discontinued part or all of first-line therapy due to
             toxicity and experienced radiographic disease progression ≤ 6 months after the last
             dose of first-line therapy

          7. Receipt of no more than 3 prior systemic therapy regimen for metastatic disease

          8. Measurable or non-measurable disease based on the Response Evaluation Criteria in
             Solid Tumors, Version 1.1 (RECIST v. 1.1)

          9. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

         10. Life expectancy &gt; 3 months

         11. Adequate renal, hepatic, and bone marrow function

         12. Leukocytes ≥4.0 x 109 / L

         13. Absolute neutrophil count (ANC) &gt; 1,500/mm3

         14. Platelet count ≥ 100,000/mm3

         15. Hemoglobin ≥ 9 g/dL (can be post-transfusion)

         16. International normalized ratio (INR) ≤ 1.5

         17. Activated partial thromboplastin time (aPTT) ≤ 1.5 times upper limit of normal (ULN)

         18. Bilirubin ≤ 1.5 times ULN

         19. ALT and AST ≤ 2.5 times ULN

         20. Creatinine ≤ 2.0 mg/dL

         21. Proteinuria ≤ 1+ by urine dipstick OR ≤ 1 g by 24-hour urine collection

         22. Patients who are able to understand the nature and purpose of the study including
             possible risks, willing to comply with the requirements, and to provide their written
             informed consent to participate in the study

        Exclusion Criteria:

          1. Concomitant treatment with anti-angiogenic therapy before progression of disease

          2. Treatment in any other clinical trial within 30 days before screening.

          3. Gastric bypass

          4. Ileostoma

          5. Other anatomical change of the gastrointestinal tract, interfering with
             gastrointestinal passage, except colostoma or colon bypass

          6. Untreated CNS metastases. Participants with treated brain metastases are eligible if
             they are clinically stable with regard to neurologic function, off steroids after
             cranial irradiation ending at least 2 weeks prior to randomization, or after surgical
             resection performed at least 28 days prior to randomization. No evidence of Grade
             greater than or equal to 1 CNS hemorrhage based on pretreatment Magnetic Resonance
             Imaging (MRI) or intravenous (IV) contrast CT scan

          7. Significant traumatic injury or surgery within the past 4 weeks

          8. Cerebrovascular accident, transient ischemic attack, or subarachnoid hemorrhage within
             the past 6 months

          9. Other malignancies within the past 5 years except for adequately treated carcinoma in
             situ of the cervix, and/or basal cell skin cancer, and/or early endometrial carcinoma

         10. Pre-existing sensory or motor neuropathy ≥ grade 2

         11. History or evidence of CNS disease (e.g., uncontrolled seizures) by neurological
             examination unless adequately treated with standard medical therapy

         12. History or evidence of thrombotic or hemorrhagic disorders, including intracranial
             hemorrhage

         13. Uncontrolled hypertension (i.e., blood pressure &gt; 160/100 mm Hg)

         14. Clinically significant cardiovascular disease, including any of the following:

               -  Myocardial infarction or unstable angina within the past 6 months

               -  New York Heart Association class III-IV congestive heart failure

               -  Poorly controlled cardiac arrhythmia despite medication, except rate controlled
                  atrial fibrillation

         15. Peripheral vascular disease ≥ grade 3 (i.e., symptomatic and interfering with
             activities of daily living requiring repair or revision)

         16. Positive for anti-typhoid IgG/IgM antibodies according to the onsite test on Day 0

         17. Hemoptysis within 6 months before randomization

         18. Esophageal varices

         19. Upper or lower gastrointestinal bleeding within 6 months before randomization

         20. Non-healing wound, incomplete wound healing, bone fracture or any history of
             gastrointestinal ulcers within three years before inclusion, or positive gastroscopy
             within 3 months before inclusion

         21. Gastrointestinal fistula

         22. Thrombolysis therapy within 4 weeks before randomization

         23. Presence of any acute or chronic systemic infection

         24. Major surgical procedures, or open biopsy within 4 weeks before randomization

         25. Chronic concurrent therapy within 2 weeks before and during the initial treatment
             period (Day 1 to Day 7):

               -  Corticosteroids (except steroids for adrenal failure or emesis prophylaxis up to
                  4 mg daily dose) or immunosuppressive agents

               -  Antibiotics

               -  Bevacizumab or any other anti-angiogenic treatment

         26. Known multi-drug resistant gram-negative bacteria

         27. History of other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug or that might affect the
             interpretation of the study results or render the patient at high risk for treatment
             complications

         28. Women of childbearing potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carsten Gruellich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Center of Tumor Diseases Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Center of Tumor Diseases</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2016</study_first_submitted>
  <study_first_submitted_qc>March 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2016</study_first_posted>
  <last_update_submitted>April 28, 2017</last_update_submitted>
  <last_update_submitted_qc>April 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

